card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Elevating Effective Outcomes with Companion Diagnostics

Elevating Effective Outcomes with Companion Diagnostics
Home / Insights / Elevating Effective Outcomes with Companion Diagnostics

The successful development and commercialization of personalized medicines often necessitate use of companion diagnostics (CDx).

Now more than ever, drug developers need an experienced global partner to advance CDx development, who understands how to navigate the technical, regulatory and commercialization nuances to enhance the chances of program success.

 

Additionally, there is a sharpening focus toward smaller populations treated with drugs for orphan indications and rare diseases, umbrella clinical trials where targeted drugs are used for multiple tumor mutations, and basket clinical trials where targeted drugs focus on multiple tumor indications.

 

For the full article, please click here.